en Pharmaceutical Biotechnology Pharmaceutical Biotechnology مقاله کامل Full Length/Original Article <div style="text-align: justify;"><span style="font-family:Times New Roman;"><span style="font-size:11pt"><span style="line-height:normal"><b><span style="font-size:10.5pt"><span style="color:black">Background: </span></span></b><span style="font-size:10.5pt"><span style="color:black">Influenza A virus (IAV) is a global health concern, increasing the exploration of alternative therapeutics. Biosurfactants (BSs) are biodegradable, non-toxic biomolecules with favorable biological activities. <i>Acinetobacter junii</i> B6, known for utilizing crude oil as a carbon and energy source, produces BSs. This study evaluated the antiviral potential of the lipopeptide biosurfactant (LPB) against H1N1/A/PR8/34 infection.</span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><b><span style="font-size:10.5pt"><span style="color:black">Methods</span></span></b><span style="font-size:10.5pt"><span style="color:black">: <i>A. junii</i> B6 LPB was extracted and characterized in our previous study. The 50% cytotoxic concentration and non-cytotoxic concentration (NCTC), defined as the concentration with no toxicity on cells, were determined by the MTT assay on MDCK cells. The NCTC was exposed to the cells in the presence of PR8 (100 TCID₅₀) under simultaneous, pre- and post-exposure combination treatments for 1 h. After 48 h of incubation, the hemagglutination and MTT assays assessed viral propagation and cell protection, respectively. Amantadine and oseltamivir served as antiviral control drugs.</span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><b><span style="font-size:10.5pt"><span style="color:black">Results: </span></span></b><span style="font-size:10.5pt"><span style="color:black">The extracted LPB caused a 1 log₂ reduction in pre- and post-exposure treatments, whereas amantadine </span>and <span style="color:black">oseltamivir </span>reduced viral titers by more than 1 <span style="color:black">log₂. Cell protection was favorable in all combination treatments</span> except for LPB co-treatment<span style="color:black">. LPB extract showed limited but notable anti-IAV activity, alongside cell protection.</span></span></span></span><br> <b><span style="font-size:10.5pt"><span style="line-height:115%"><span style="color:black">Conclusion: </span></span></span></b><span style="font-size:10.5pt"><span style="line-height:115%"><span style="color:black">While<b> </b>LPB is less potent than amantadine and oseltamivir, its non-toxic and environmentally friendly nature warrants further study. As surfactants act on the lipid envelope, viral proteins, and nucleocapsid proteins, LPB could be potentially used as an adjuvant with other antiviral agents to control the prevalence of viral diseases and improve therapeutic outcomes.</span></span></span> </span></div> Acinetobacter junii, Antiviral agents, Influenza A virus, Lipopeptides 165 173 http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-6462-1&slc_lang=en&sid=1 Amir Mohammad Bagheri amirmobagheri0077@gmail.com 0000-0002-7375-4888 No Herbal and Traditional Medicines Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran Hamid Forootanfar forootanfar@yahoo.com 0000-0001-5049-7674 No Pharmaceutical Sciences and Cosmetic Products Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran Gholamreza Dehghannoudeh grdehghannoudeh@gmail.com 0000-0003-1420-2650 No Department of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran Mohammad Amin Raeisi Estabragh aminr374@yahoo.com 0000-0001-5992-1654 No Department of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran Ibrahim M. Banat im.banat@ulster.ac.uk 0000-0001-8964-2840 No School of Biomedical Sciences, Faculty of Life & Health Sciences, Ulster University, Coleraine BT52 1SA, N. Ireland, UK Hosnieh Sokhandan hosnie_sokhandan@yahoo.com 0009-0003-1750-2090 No Hadiseh Shokouhi shokohi.hadis@gmail.com 0000-0002-4325-6554 No Influenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran; 7Autophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Mandana Ohadi mandanaohady@gmail.com 0000-0001-7251-3751 Yes Pharmaceutics Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran Parvaneh Mehrbod* mehrbode@yahoo.com 0000-0002-8391-9228 No Influenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran